Release of calcitonin gene-related peptide in cardiac anaphylaxis.
We have investigated the antigen-stimulated release of calcitonin gene-related peptide (CGRP) from ovalbumin-sensitized guinea-pig isolated hearts and the interaction with other mediators of anaphylaxis released concomitantly. It was found that antigen challenge caused a significant increase of CGRP release (from basal 31.2 +/- 2.9 to 51.6 +/- 4.9 fmol/5 min). Anaphylactic CGRP release was significantly attenuated in the presence of the cyclooxygenase inhibitor indomethacin while the 5-lipoxygenase inhibitor Bay-X1005 ((R)-2-[4-quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid) had no significant effect. Combined treatment with the histamine receptor (H1,H2) antagonists mepyramine and cimetidine also significantly attenuated anaphylactic release of CGRP. Under control conditions antigen injection increased release of cysteinyl-leukotrienes (LT), thromboxane (TXB2) and 6-keto-prostaglandin (PG)F1 alpha from basal values of 0.96 +/- 0.09, 2.7 +/- 0.7 and 3.4 +/- 0.28 ng/5 min respectively, to 5.9 +/- 0.9, 48.4 +/- 3.4 and 6.9 +/- 1.4 ng/5 min. Indomethacin abolished the release of cyclooxygenase products of arachidonate metabolism and simultaneously increased cysteinyl-LT release significantly (8.8 +/- 1.4 ng/5 min). Conversely Bay-X1005 completely abolished cysteinyl-LT release and had no significant effect on anaphylactic release of TXB2 and 6-keto-PGF1 alpha. Simultaneous blockade of H1 and H2 receptors abolished release of 6-keto-PGF1 alpha, while release of TXB2 and cysteinyl-LT was not significantly affected. The results indicate that CGRP is not a primary mediator of the immediate hypersensitivity reaction of the heart, but is in turn released by arachidonic acid metabolites of the cyclooxygenase pathway and histamine. In contrast, LT obviously do not contribute to anaphylactic CGRP release. CGRP is a potent coronary vasodilator and could act as endogenous functional antagonist of vasoconstrictor mediators also released during cardiac anaphylaxis such as cysteinyl-LT, platelet activating factor and TXA2.
Schuligoi
R
R
Department of Experimental and Clinical Pharmacology, University of Graz, Austria.
Amann
R
R
Donnerer
J
J
Peskar
B A
BA
D015121:6-Ketoprostaglandin F1 alpha / Q000276:immunology / Q000378:metabolism; D000707:Anaphylaxis / Q000276:immunology / Q000378:metabolism* / Q000503:physiopathology; D000818:Animals; D015740:Calcitonin Gene-Related Peptide / Q000276:immunology / Q000378:metabolism*; D002927:Cimetidine / Q000494:pharmacology; D003326:Coronary Circulation / Q000276:immunology / Q000502:physiology; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D006168:Guinea Pigs; D006321:Heart / Q000503:physiopathology*; D006634:Histamine H1 Antagonists / Q000494:pharmacology; D006635:Histamine H2 Antagonists / Q000494:pharmacology; D066298:In Vitro Techniques; D007213:Indomethacin / Q000494:pharmacology; D017997:Leukotriene C4 / Q000276:immunology / Q000378:metabolism; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology; D009206:Myocardium / Q000276:immunology / Q000378:metabolism*; D010047:Ovalbumin / Q000276:immunology; D011738:Pyrilamine / Q000494:pharmacology; D011804:Quinolines / Q000494:pharmacology; D013929:Thromboxane B2 / Q000276:immunology / Q000378:metabolism
D016861:Cyclooxygenase Inhibitors; D006634:Histamine H1 Antagonists; D006635:Histamine H2 Antagonists; D016859:Lipoxygenase Inhibitors; D011804:Quinolines; C079315:2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid; D017997:Leukotriene C4; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D002927:Cimetidine; D010047:Ovalbumin; D011738:Pyrilamine; D015740:Calcitonin Gene-Related Peptide; D007213:Indomethacin